Peptides targeting voltage-gated calcium channels

Current Pharmaceutical Design

Volumn 14, Issue 24, 2008, Pages 2480-2491

  Norton, Raymond S ^a   McDonough, Stefan I ^b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b AMGEN INC   (United States)

Author keywords

Amino acid; Blockers; Cone shells; Human therapeutics; Modulators; Peptides; Pharmacology; Spiders; Structure function relationships; Voltage Gated Calcium Channels (VGCCs)

Indexed keywords

AMLODIPINE BESYLATE; CALCICLUDINE; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; FS 2; INSECT VENOM; KP 4; MIBEFRADIL; NIFEDIPINE; NMED 160; OMEGA AGATOXIN; OMEGA AGATOXIN IIIA; OMEGA AGATOXIN IVA; OMEGA AGATOXIN IVB; OMEGA AGATOXIN IVC; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN GVIA; OMEGA CONOTOXIN MVIIA; OMEGA CONOTOXIN MVIIC; OMEGA GRAMMATOXIN SIA; OPIATE; PEIRATES TURPIS TOXIN; PHENOTOXIN IIA; PLACEBO; PLTX II; POLYPEPTIDE; SNX 325; SNX 482; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

AMINO ACID SEQUENCE; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; CYSTINE KNOT MOTIF; DIZZINESS; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; NEUROPATHIC PAIN; NONHUMAN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

AMINO ACID SEQUENCE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; VENOMS;

EID: 52949117550     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785777478     Document Type: Review

References (142)

1. 2+ channels. In: Ion channels in disease. San Diego, CA. Academic Press; 2000.
2. Hille B. Voltage-gated calcium channels. In: Ion channels of excitable membranes. Sunderland, MA. Sinauer Associates; 2001.
3. 2+ channel β-subunits: structural insights AID our understanding. Trends Pharmacol Sci 2004; 25: 626-32.
4. 2+ channels. Annu Rev Cell Dev Biol 2000; 16: 521-55.
5. Catterall WA, Cestele S, Yarov-Yarovoy V, Yu FH, Konoki K, Scheuer T. Voltage-gated ion channels and gating modifier toxins. Toxicon 2007; 49: 124-41.
6. Sather WA, McCleskey EW. Permeation and selectivity in calcium channels. Annu Rev Physiol 2003; 65: 133-59.
7. Osten P, Stern-Bach Y. Learning from stargazin: the mouse, the phenotype and the unexpected. Curr Opin Neurobiol 2006; 16: 275-80.
8. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 1996; 271: 5768-76.
9. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, et al. Identification of the α2-δ-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006; 103: 17537-42.
10. Iannetti GD, Zambreanu L, Wise RG, Buchanan TJ, Huggins JP, Smart TS, et al. Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. Proc Natl Acad Sci USA 2005; 102: 18195-200.
11. Triggle DJ. L-type calcium channels. In: Triggle DJ, Gopalakrishnan M, Rampe D, Zheng W, Eds, Voltage-Gated Ion Channels as Drug Targets. Wiley-VCH, Weinheim, Germany, 2006; 100-140.
12. Olivera BM, Miljanich GP, Ramachandran J, Adams ME. Calcium channel diversity and neurotransmitter release: the ω-conotoxins and ω-agatoxins. Annu Rev Biochem 1994; 63: 823-67.
13. Norton RS, Olivera BM. Conotoxins down under. Toxicon 2006; 48: 780-98.
14. Norton RS, Baell JB, Angus JA. In: McDonough SI, Ed, Calcium Channel Pharmacology. Calcium channel blocking polypeptides: structure, function and molecular mimicry. Kluwer Academic/Plenum Publishers, New York 2004; 143-81.
15. Han TS, Teichert RW, Olivera BM, Bulaj G. Conus venoms - a rich source of peptide-based therapeutics. Curr Pharm Des 2008; in press.
16. King GF. Modulation of insect Ca(v) channels by peptidic spider toxins. Toxicon 2007; 49: 513-30.
17. Ertel EA, Warren VA, Adams ME, Griffin PR, Cohen CJ, Smith MM. Type III ω-agatoxins: a family of probes for similar binding sites on L- and N-type calcium channels. Biochemistry 1994; 33: 5098-108.
18. Yan L, Adams ME. The spider toxin ω-Aga IIIA defines a high affinity site on neuronal high voltage-activated calcium channels. J Biol Chem 2000; 275: 21309-16.
19. Mintz IM, Venema VJ, Swiderek KM, Lee TD, Bean BP, Adams ME. P-type calcium channels blocked by the spider toxin ω-Aga-IVA. Nature 1992; 355: 827-9.
20. Adams ME, Mintz IM, Reily MD, Thanabal V, Bean BP. Structure and properties of ω-agatoxin IVB, a new antagonist of P-type calcium channels. Mol Pharmacol 1993; 44: 681-8.
21. Heck SD, Siok CJ, Krapcho KJ, Kelbaugh PR, Thadeio PF, Welch MJ, et al. Functional consequences of posttranslational isomerization of Ser46 in a calcium channel toxin. Science 1994; 266: 1065-8.
22. Kuwada M, Teramoto T, Kumagaye KY, Nakajima K, Watanabe T, Kawai T, et al. ω-agatoxin-TK containing D-serine at position 46, but not synthetic [L-Ser46)agatoxin-TK, exerts blockade of P-type calcium channels in cerebellar Purkinje neurons. Mol Pharmacol 1994; 46: 587-93.
23. Bindokas VP, Adams ME. ω-Aga-I: a presynaptic calcium channel antagonist from venom of the funnel web spider, Agelenopsis aperta. J Neurobiol 1989; 20: 171-88.
24. 2+ channel currents by the funnel web spider toxin ω-Aga-IA. Mol Pharmacol 1990; 38: 711-8.
25. Venema VJ, Swiderek KM, Lee TD, Hathaway GM, Adams ME. Antagonism of synaptosomal calcium channels by subtypes of ω-agatoxins. J Biol Chem 1992; 267: 2610-5.
26. Adams ME, Bindokas VP, Hasegawa L, Venema VJ. ω-agatoxins: novel calcium channel antagonists of two subtypes from funnel web spider ( Agelenopsis aperta) venom. J Biol Chem 1990; 265: 861-7.
27. Bindokas VP, Venema VJ, Adams ME. Differential antagonism of transmitter release by subtypes of ω-agatoxins. J Neurophysiol 1991; 66: 590-601.
28. Cordeiro Mdo N, de Figueiredo SG, Valentim Ado C, Diniz CR, von Eickstedt VR, Gilroy J, et al. Purification and amino acid sequences of six Tx3 type neurotoxins from the venom of the Brazilian 'armed' spider Phoneutria nigriventer (Keys). Toxicon 1993; 31: 35-42.
29. Leao RM, Cruz JS, Diniz CR, Cordeiro MN, Beirao PS. Inhibition of neuronal high-voltage activated calcium channels by the ω-Phoneutria nigriventer Tx3-3 peptide toxin. Neuropharmacology 2000; 39: 1756-67.
30. Miranda DM, Romano-Silva MA, Kalapothakis E, Diniz CR, Cordeiro MN, Santos TM, et al. Phoneutria nigriventer toxins block tityustoxin-induced calcium influx in synaptosomes. Neuroreport 1998; 9: 1371-3.
31. Kalapothakis E, Penaforte CL, Leao RM, Cruz JS, Prado VF, Cordeiro MN, et al. Cloning, cDNA sequence analysis and patch clamp studies of a toxin from the venom of the armed spider (Phoneutria nigriventer). Toxicon 1998; 36: 1971-80.
32. Diniz CR, Cordeiro Mdo N, Junor LR, Kelly P, Fischer S, Reimann F, et al. The purification and amino acid sequence of the lethal neurotoxin Tx1 from the venom of the Brazilian 'armed' spider Phoneutria nigriventer. FEBS Lett 1990; 263: 251-3.
33. Santos RG, Diniz CR, Cordeiro MN, De Lima ME. Binding sites and actions of Txl, a neurotoxin from the venom of the spider Phoneutria nigriventer, in guinea pig ileum. Braz J Med Biol Res 1999; 32: 1565-9.
34. Cassola AC, Jaffe H, Fales HM, Castro Afeche S, Magnoli F, Cipolla-Neto J. omega-phonetoxin-IIA: a calcium channel blocker from the spider Phoneutria nigriventer. Pflugers Arch 1998; 436: 545-52.
35. Dos Santos RG, Van Renterghem C, Martin-Moutot N, Mansuelle P, Cordeiro MN, Diniz CR, et al. Phoneutria nigriventer ω-phonetoxin IIA blocks the Cav2 family of calcium channels and interacts with ω-conotoxin-binding-sites. J. Biol Chem 2002; 277: 13856-62.
36. Lampe RA, Defeo PA, Davison MD, Young J, Herman JL, Spreen RC, et al. Isolation and pharmacological characterization of ω-grammotoxin SIA, a novel peptide inhibitor of neuronal voltage-sensitive calcium channel responses. Mol Pharmacol 1993; 44: 451-60.
37. McDonough SL, Lampe RA, Keith RA, Bean BP. Voltage-dependent inhibition of N- and P-type calcium channels by the peptide toxin ω-grammotoxin-SIA. Mol Pharmacol 1997; 52: 1095-104.
38. + channels. Proc Natl Acad Sci USA 1998; 95:8585-9.
39. Newcomb R, Szoke B, Palma A, Wang G, Chen X, Hopkins W, et al. Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochemistry 1998; 37: 15353-62.
40. Hagiwara K, Sakai T, Miwa K, Kawai N, Nakajima T. Complete amino-acid sequence of a new type of neurotoxin from the venom of the spider, Agelena opulenia. Biomed Res 1991; 11: 181-6.
41. Inui T, Hagiwara K, Nakajima K, Kimura T, Nakajima T, Sakakibara S. Synthesis and disulfide structure determination of agelenin; identification of the carboxy-terminus as an amide form. Pept Res 1992; 5: 140-4.
42. Newcomb R, Palma A, Fox J, Gaur S, Lau K, Chung D, et al. SNX-325, a novel calcium antagonist from the spider Segestria florentina. Biochemistry 1995; 34: 8341-7.
43. Sutton KG, Siok C, Stea A, Zamponi GW, Heck SD, Volkmann RA, et al. Inhibition of neuronal calcium channels by a novel peptide spider toxin, DW13.3. Mol Pharmacol 1998; 54: 407-18.
44. Liang SP, Zhang DY, Pan X, Chen Q, Zhou PA. Properties and amino acid sequence of huwentoxin-I, a neurotoxin purified from the venom of the Chinese bird spider Selenocosmia huwena. Toxicon 1993; 31: 969-78.
45. 2+ channels in differentiated NG108-15 cells, a patch-clamp study. Toxicon 2001; 39:491-8.
46. 2+ channels. Toxicon 2007; 50: 993-1004.
47. Wang XH, Connor M, Wilson D, Wilson HI, Nicholson GM, Smith R, et al Discovery and structure of a potent and highly specific blocker of insect calcium channels. J Biol Chem 2001; 276: 40306-12.
48. Branton WD, Rudnick MS, Zhou Y, Eccleston ED, Fields GB, Bowers LD. Fatty acylated toxin structure. Nature 1993; 365: 496-7.
49. Rash LD, Hodgson WC. Pharmacology and biochemistry of spider venoms. Toxicon 2002; 40: 225-54.
50. Chuang RS, Jaffe H, Cribbs L, Perez-Reyes E, Swartz KJ. Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin. Nat Neurosci 1998; 1: 668; 74.
51. Sidach SS, Mintz IM. Kurtoxin, a gating modifier of neuronal high-and low-threshold Ca channels. J Neurosci 2002; 22: 2023-34.
52. Morrissette J, Beurg M, Sukhateva M, Coronado R. Purification and characterization of ryanotoxin a peptide with actions similar to those of ryanodine. Biophys J 1996; 71: 707-21.
53. Zamudio FZ, Conde R, Arevalo C, Becerril B, Martin BM, Valdivia HH, et al The mechanism of inhibition of ryanodine receptor channels by imperatoxin I, a heterodimeric protein from the scorpion Pandinus imperator. J Biol Chem 1997; 272: 11886-94.
54. 2+ release channels/ ryanodine receptors. FEDS Lett 19,97; 405: 385-9.
55. 2+ release channel/ryanodine receptors. FEBS Lett 2000; 469: 179-85.
56. de Weille JR, Schweitz H, Maes P, Tartar A, Lazdunski M. Calciseptine, a peptide isolated from black mamba venom is a specific blocker of the L-type calcium channel. Proc Natl Acad Sci USA 1991; 88: 2437-40.
57. Yasuda O, Morimoto S,, Jiang B, Kuroda H, Kimura T, Sakakibara S, et al. FS2. a mamba venom toxin, is a specific blocker of the L-type calcium channels. Artery 1994; 21: 287-302.
58. 2+ channels with a high affinity for L-type channels in cerebellar granule neurons. Proc Natl Acad Sci USA 1994; 91: 878-82.
59. Nakakura N, Hietter H, Van Dorsselaer A, Luu B. Isolation and structural determination of three peptides from the insect Locusta migratoria, Identification of a deoxyhoxose-linked peptide. Eur J Biochem 1992; 204:147-53.
60. Boigegrain RA, Mattras H, Brehelin M, Paroutaud P, Coletti-Previero MA. Insect immunity: two proteinase inhibitors from hemolymph of Locusta migratoria. Biochem Biophys Res Commun 1992; 189:790-3.
61. Scott RH, Gorton VJ, Harding L, Patel D, Pacey S, Kellenberger C, et al Inhibition of neuronal high voltage-activated calcium channels by insect peptides: a comparison with the actions of ω-conotoxin GVIA. Neuropharmacology 1997; 36: 195-208.
62. Corzo G, Adachi-Akahane S, Nagao T, Kusui Y, Nakajima T. Novel peptides from assassin bugs (Hemiptera: Reduviidae): isolation, chemical and biological characterization. FEBS Lett 2001; 499: 256-61.
63. Narasimhan L, Singh J, Humblet C, Guruprasad K; Blundell T. Snail and spider toxmis share a similar tertiary structure and 'cystine motif. Nat Struct Biol 1994; 1: 850-2.
64. Pallaghy PK, Nielsen KJ, Craik DJ, Norton RS. A common structural motif incorporating a cystine knot and a triple-stranded β-sheet in toxic and inhibitory polypeptides. Protein Sci 1994; 3: 1833-9.
65. Norton RS, Pallaghy PK. The cystine knot structure of ion channel toxins and related polypeptides. Toxicon 1998; 36: 1573-83.
66. Yu H, Rosen MK, Saccomano NA, Phillips D, Volkmann RA, Schreiber SL. Sequential assignment and structure determination of spider toxin ω-Aga-IVB. Biochemistry 1993; 32: 13123-9.
67. Reily MD, Thinabal V, Adams ME. The solution structure of ω-Aga-IVB, a P-type calcium channel antagonist from venom of the funnel web spider, Agelenopsis aperta. J Biomol NMR 1995; 5: 122-32.
68. Reily MD, Holub KE, Gray WR, Norris TM, Adams ME. Structure-activity relationships for P-type calcium channel-selective ω-agatoxins. Nat Struct Biol 1994; 1: 853-6.
69. Kim JI, Konishi S, Iwai H, Kohno T, Gouda H, Shimada I, et al. Three-dimensional solution structure of the calcium channel antagonist ω-agatoxin IVA: consensus molecular folding of calcium channel blockers. J Mol Biol 1995; 250: 659-71.
70. 2+ channel. J Mol Biol 2002; 321: 517-26.
71. Pallaghy PK, Duggan BM, Pennington MW, Norton RS. Three-dimensional structure in solution of the calcium channel blocker ω-conotoxin. J Mol Biol 1993; 234:405-20.
72. Pallaghy PK, Norton RS. Refined solution structure of ω-conotoxin GVIA: implications for calcium channel binding. J Pept Res 1999; 53: 343-51.
73. Buczek O, Wei D, Babon JJ, Yang X, Fiedler B, Chen P, et al. Structure and sodium channel activity of an excitatory II-superfamily conotoxin. Biochemistry 2007; 46: 9929-40.
74. Qu Y, Liang S, Ding J, Liu X, Zhang R, Gu X. Proton nuclear magnetic resonance studies on huwentoxin-I from the venom of the spider Selenocosmia huwena: 2. Three-dimensional structure in solution. J Protein Chem 1997; 16: 565-74.
75. 2+ channel blocker calcicludine. Proteins 1999; 34: 520-32.
76. Nishio H, Katoh E, Yamazaki T, Inui T, Nishiuchi Y, Kimura T. Structure-activity relationships of calcicludine and dendrotoxin-I, homologous peptides acting on different targets, calcium and potassium channels. Biochem Biophys Res Commun 1999; 262: 319-21.
77. Mosbah A, Kharrat R, Fajloun Z, Renisio JG, Blanc E, Sabatier JM, et al. A new fold in the scorpion toxin family, associated with an activity on a ryanodine-sensitive calcium channel. Proteins 2000; 40: 436-42.
78. Samso M, Trujillo R, Gurrola GB, Valdivia HH, Wagenknecht T. Three-dimensional location of the imperatoxin A binding site on the ryanodine receptor. J Cell Biol 1999; 146: 493-9.
79. Bernard C, Corzo G, Mosbah A, Nakajima T, Darbon H. Solution structure of Ptu1, a toxin from the assassin bug Peirates turpis that blocks the voltage-sensitive calcium channel N-type. Biochemistry 2001; 40: 12795-800.
80. Mer G, Kellenberger C, Koehl P, Stote R, Sorokine O, Van Dorsselaer A, et al. Solution structure of PMP-D2, a 35-residue peptide isolated from the insect Locusta migratoria. Biochemistry 1994; 33: 15397-407.
81. Mer G, Hietter H, Kellenberger C, Renatus M, Luu B, Lefevre JF. Solution structure of PMP-C: a new fold in the group of small serine proteinase inhibitors. J Mol Biol 1996; 258: 158-71.
82. 2+ channel inhibitor. Structure 1995; 3: 805-14.
83. Gage MJ, Rane SG, Hockerman GH, Smith TJ. The virally encoded fungal toxin KP4 specifically blocks L-type voltage-gated calcium channels. Mol Pharmacol 2002; 61: 936-44.
84. Spelbrink RG, Dilmac N, Allen A, Smith TJ, Shah DM, Hockerman GH. Differential antifungal and calcium channel-blocking activity among structurally related plant defensins. Plant Physiol 2004; 135: 2055-67.
85. 2+ channel blocking and antifungal activities. Biochemistry 2007; 46: 13733-41.
86. Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000; 26: 13-25.
87. + channel: peptide and channel residues mediating molecular recognition. Neuron 1994; 12: 1377-88.
88. + channel pore through mutant cycles with a peptide inhibitor. Science 1995; 268: 307-10.
89. McDonough SI, Boland LM, Mintz IM, Bean BP. Interactions among toxins that inhibit N-type and P-type calcium channels. J Gen Physiol 2002; 119: 313-28.
90. McDonough SI. Gating modifier toxins of voltage-gated calcium channels. Toxicon 2007; 49: 202-12.
91. Ikeda SR. Voltage-dependent modulation of N-type calcium channels by G-protein β γ subunits. Nature 1996; 380: 255-8.
92. 2+ channel gating. Proc Natl Acad Sci USA 2000; 97: 13943-8.
93. Bean BP, Nowycky MC, Tsien RW. β-adrenergic modulation of calcium channels in frog ventricular heart cells. Nature 1984; 307: 371-5.
94. Lee SY, MacKinnon R. A membrane-access mechanism of ion channel inhibition by voltage sensor toxins from spider venom. Nature 2004; 430: 232-5.
95. Bourinet E, Soong TW, Sutton K, Slaymaker S, Mathews E, Monteil A, et al. Splicing of alpha 1A subunit gene generates phenotypic variants of P- and Q-type calcium channels. Nat Neurosci 1999; 2: 407-15.
96. Hans M, Urrutia A, Deal C, Brust PF, Stauderman K, Ellis SB, et al. Structural elements in domain IV that influence biophysical and pharmacological properties of human α1A-containing high-voltage-activated calcium channels. Biophys J 1999; 76: 1384-400.
97. Winterfield JR, Swartz KJ. A hot spot for the interaction of gating modifier toxins with voltage-dependent ion channels. J Gen Physiol 2000; 116: 637-44.
98. Feng ZP, Hamid J, Doering C, Bosey GM, Snutch TP, Zamponi GW. Residue Gly1326 of the N-type calcium channel 1B subunit controls reversibility of ω-conotoxin GVIA and MVIIA block. J Biol Chem 2001; 276: 15728-35.
99. Boland LM, Morrill JA, Bean BP. ω-Conotoxin block of N-type calcium channels in frog and rat sympathetic neurons. J Neurosci 1994; 14: 5011-27.
100. McDonough SI. In: McDonough SI, Ed, Calcium Channel Pharmacology. Peptide toxin inhibition of voltage gated calcium channels: selectivity and mechanism. Kluwer Academic/Plenum Publishers, New York 2004.
101. Nielsen KJ, Schroeder T, Lewis R. Structure-activity relationships of ω-conotoxins at N-type voltage-sensitive calcium channels. J Mol Recognit 2000; 13: 55-70.
102. Schroeder CI, Doering CJ, Zamponi GW, Lewis RJ. N-type calcium channel blockers: novel therapeutics for the treatment of pain. Med Chem 2006; 2: 535-43.
103. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004; 11: 3029-40.
104. McGivern JG. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discov Today 2006; 11: 245-53.
105. Atanassoff PG, Hartmannsgruber MW, Thrasher J, Wermeling D, Longton W, Gaeta R, et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med 2000; 25: 274-8.
106. Taqi DGI, Bhakta B, Movva V, Ward S, Jenson M, Royal M. Intrathecal ziconotide effect on neuropathic symptoms and potential for adjunctive use with opiates: a retrospective review in 25 patients. Pain Med 2002; 3:180-1.
107. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004; 291: 63-70.
108. Maggi CA, Tramontana M, Cecconi R, Santicioli P. Neurochemical evidence for the involvement of N-type calcium channels in transmitter secretion from peripheral endings of sensory nerves in guinea pigs. Neurosci Lett 1990; 114: 203-6.
109. Gruner W, Silva LR. ω-conotoxin sensitivity and presynaptic inhibition of glutamatergic sensory neurotransmission in vitro. J Neurosci 1994; 14(5 Pt 1): 2800-8.
110. 3H]acetylcholine from rat habenula slices. Neurochem Res 1997; 22: 967-75.
111. Lewis RJ, Nielsen KJ, Craik DJ, Loughnan ML, Adams DA, Sharpe IA, et al. Novel ω-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 2000; 275: 35335-44.
112. Scott DA, Wright CE, Angus JA. Actions of intrathecal ω-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 2002; 451: 279-86.
113. McDonough SI, Bean BP. State-dependent drug interaction with ion channels. In: Triggle DJ, Gopalakrishnan M, Rampe D, Zheng W, Eds, Voltage-Gated Ion Channels as Drug Targets. Wiley-VCH, Weinheim, Germany, 2006; 19-36.
114. Triggle DJ. L-type calcium channels. Curr Pharm Des 2006; 12: 443-57.
115. Po AL, Zhang WY. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 1998; 351: 1829-30.
116. Moosmang S, Haider N, Bruderl B, Welling A, Hofmann F. Anti-hypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2. Circ Res 2006; 98: 105-10.
117. Lory P, Chemin J. Towards the discovery of novel T-type calcium channel blockers. Expert Opin Ther Targets 2007; 11: 717-22.
118. Jing X, Li DQ, Olofsson CS, Salehi A, Surve VV, Caballero J, et al. Cav2.3 calcium channels control second-phase insulin release. J Clin Invest 2005; 115: 146-54.
119. 2+ channels as therapeutic targets in the nervous system. Curr Opin Pharmacol 2008; 8: 33-41.
120. Bourinet E, Alloui A, Monteil A, Barrere C, Couette B, Poirot O, et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 2005; 24: 315-24.
121. 2+ channel gene CACNL1A4. Cell 1996; 87: 543-52.
122. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003; 4: 386-98.
123. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007; 447: 1081-6.
124. Sullivan JK, McGivern JG, Miranda LP, Nguyen HQ, Walker KW, Hu S, et al. Peptide toxins as therapeutic agents. WIPO Publication WO 2006/ 116156 2006.
125. Gomez-Varela D, Zwick-Wallasch E, Knotgen H, Sanchez A, Hettmann T, Ossipov D, et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res 2007; 67: 7343-9.
126. 2+ currents and mimics cerebellar ataxia in vivo. Proc Natl Acad Sci USA 2008; 105: 2705-10.
127. Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther 2004; 309: 469-75.
128. Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and Aβ fibril disaggregation. Bioconjug Chem 2007; 18: 447-55.
129. Baell JB, Forsyth SA, Gable RW, Norton RS, Mulder RJ. Design and synthesis of type-III mimetics of ω-conotoxin GVIA. J Comput Aided Mol Des 2001; 15: 1119-36.
130. Baell JB, Harvey AJ, Norton RS. Design and synthesis of type-III mimetics of ShK toxin. J Comput Aided Mol Des 2002; 16: 245-62.
131. Baell JB, Duggan PJ, Lok YP. ω-Conotoxins and approaches to their nonpeptide mimetics. Aust J Chem 2004; 57:179-185.
132. Lew MJ, Flinn JP, Pallaghy PK, Murphy R, Whorlow SL, Wright CE, et al. Structure-function relationships of ω-conotoxin GVIA. Synthesis, structure, calcium channel binding, and functional assay of alanine-substituted analogues. J Biol Chem 1997; 272: 12014-23.
133. Flinn JP, Pallaghy PK, Lew MJ, Murphy R, Angus JA, Norton RS. Roles of key functional groups in ω-conotoxin GVIA synthesis, structure and functional assay of selected peptide analogues. Eur J Biochem 1999; 262: 447-55.
134. Baell JB, Duggan PJ, Forsyth SA, Lewis RJ, Lok YP, Schroeder CI, et al. Synthesis and biological evaluation of anthranilamide-based non-peptide mimics of ω-conotoxin GVIA. Tetrahedron 2006; 62: 7284-92.
135. Baell JB, Duggan PJ, Forsyth SA, Lewis RJ, Lok YP, Schroeder CI. Synthesis and biological evaluation of nonpeptide mimetics of ω-conotoxin GVIA. Bioorg Med Chem 2004; 12: 4025-37.
136. Xu W, Lipscombe D. Neuronal Ca(v)1.3 α1 L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines. J Neurosci 2001; 21: 5944-51.
137. Tottene A, Volsen S, Pietrobon D. α1E subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties. J Neurosci 2000; 20: 171-8.
138. Kang HW, Moon HJ, Joo SH, Lee JH. Histidine residues in the IS3-IS4 loop are critical for nickel-sensitive inhibition of the Cav2.3 calcium channel. FEBS Lett 2007; 581: 5774-80.
139. Koradi R, Billeter M, Wüthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 1996; 14: 29-32.
140. Darbar D, Roden DM. Future of antiarrhythmic drugs. Curr Opin Cardiol 2006; 21(4): 361-7.
141. Miura S, Saku K. Regulation of angiogenesis and angiogenic factors by cardiovascular medications. Curr Pharm Des 2007; 13(20): 2113-7.
142. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr Pharm Des 2008; 14(5): 487-95.